The cannabis industry is facing an existential shift. With the recent filing of major federal racketeering class actions, such as Murray v. Cresco Labs and Duke v. Curaleaf, Multi-State Operators (MSOs) are no longer just fighting for market share; they are fighting to protect their balance sheets against the threat of RICO (the Racketeer Influenced and Corrupt Organizations Act). Originally designed to dismantle organized crime syndicates, RICO has been repurposed by plaintiffs’ attorneys into a high-stakes litigation weapon. Because the statute allows for treble damages (meaning a court can triple the total financial award) these lawsuits have become the industry’s equivalent of a “thermonuclear” legal threat. Plaintiffs in these “Big Tobacco-style” suits allege a systemic conspiracy, claiming MSOs artificially inflated consumer prices while concealing health risks. However, these claims often crumble under the weight of objective market reality. By leveraging forensic economic analysis and verified wholesale spot price data, defense counsel can move beyond conjecture and empirically prove that retail pricing is a function of transparent market forces, not a manufactured enterprise of deception.
The central premise of the plaintiffs’ economic injury argument is that consumers were induced to “overpay” for products due to misrepresented therapeutic benefits. To succeed, the plaintiffs must convince a jury that the price they paid at a dispensary was significantly higher than the “true” market value, and that this premium was the result of racketeering rather than standard market variables like supply chain costs, state level regulatory burdens, and wholesale commodity volatility. To counter this, defense counsel needs more than just internal corporate testimony; they need a forensic market baseline.
When we structure our wholesale spot price data for legal defense, we transform static numbers into an evidentiary baseline. Here is how this data is being structured to refute inflation claims:
We map regional retail prices against our independent wholesale spot price indexes. If retail prices fluctuate in direct correlation with wholesale commodity shifts (e.g., harvest seasonality, state level supply gluts, or regulatory-induced shortages), we can empirically demonstrate that retail pricing followed market-driven supply/demand curves, not an arbitrary pricing strategy designed to deceive.
Not all cannabis costs are created equal. By layering our pricing data over state-specific regulatory hurdles, such as mandatory testing requirements, seed-to-sale tracking software fees, and varying excise tax structures, we can build a “Regulatory Cost Pass-Through” exhibit. This demonstrates that a portion of the retail price is a direct result of government mandated compliance, effectively negating the claim that the price “premium” is an indicator of fraudulent inflation.
The RICO complaint relies on the idea that defendants acted uniquely in their pricing behaviors. By presenting historical data showing that our benchmarked spot prices across the entire industry moved in tandem during the periods in question, defense teams can prove that the MSOs were simply participants in a broader, transparent market environment. This dismantles the “enterprise” and “conspiracy” theories essential to a RICO claim.
Ultimately, the success of these high-stakes defenses will hinge on the credibility of the economic evidence presented. Plaintiffs rely on a narrative of “artificial inflation,” but narrative is no match for empirical data. By benchmarking retail pricing against independent, state specific commodity indexes, MSOs can effectively dismantle the “causation” and “injury” elements required for RICO standing. Forensic economics is not merely a post mortem accounting tool; it is a vital evidentiary shield that allows operators to pivot from a defensive stance to one grounded in the objective reality of the wholesale supply chain. As litigation accelerates, data driven transparency will be the most effective hedge against predatory legal claims.
Learn how our Litigation Support Desk helps MSOs defend against price inflation claims.
Cannabis Benchmarks® is published by New Leaf Data Services, LLC, an independent price reporting agency with 11+ years of wholesale pricing data across 27+ U.S. cannabis markets. IOSCO-aligned. Nasdaq & CME listed.